Compare Amgen, Inc. (AMGN) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Omnicom Group Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Omnicom Group Inc. trades at $81.93 (market cap $23.35B). The key difference: Amgen, Inc. is far larger — about 8.4× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (3.91%). Which is the better fit depends on your goals.
| AMGN | OMC | |
|---|---|---|
Market Cap | $196.12B | $23.35B |
Sector | Health | Media |
52-Week High | $388.16 | $85.80 |
52-Week Low | $271.18 | $67.27 |
Enterprise Value | $241.41B | $30.58B |
Dividend Yield | 2.77% | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Omnicom Group (OMC) trades at $81.93, up 1.36% on the day, with a bullish technical outlook driven by moving averages and a consensus analyst price target of $105.75. The company reported revenue of $17.27 billion in 2025, though net income was negative $54.5 million, reflecting margin pressure. Recent news highlights major client wins, including IBM and Netflix partnerships, and strong free cash flow generation of $2.94 billion from operations.
OMC presents a value opportunity with a low P/E of 12.16 and positive earnings beats in recent quarters, but faces risks from intense competition and fluctuating profitability. The stock's upside potential is supported by analyst optimism and strategic expansions in AI and streaming advertising, though investors should monitor margin recovery and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
